{"doc_id": "si-2022-0057-reg-1", "parent_doc_id": "si-2022-0057", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 57 of 2022", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2022, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 2) Regulations 2022. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2022” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 2) regulation 2022 (2) collective citation medicinal product (prescription control supply) regulation 2003 2022 includes regulation", "start_char": 615, "end_char": 905, "source_path": "downloads\\2022\\2022_0056.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6fbfaba414b8fa4eff5860fed25d8d4c08179d960350a1ead1df62c53e4611b1", "cross_refs": []}
{"doc_id": "si-2022-0057-reg-2", "parent_doc_id": "si-2022-0057", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 57 of 2022", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2022, "heading": "In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "2. \n\nIn these Regulations “Principal Regulations” means the Medicinal \nProducts (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of \n2003).", "text_norm": "2 regulation principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003)", "start_char": 905, "end_char": 1066, "source_path": "downloads\\2022\\2022_0056.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6fbfaba414b8fa4eff5860fed25d8d4c08179d960350a1ead1df62c53e4611b1", "cross_refs": []}
{"doc_id": "si-2022-0057-reg-3", "parent_doc_id": "si-2022-0057", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 57 of 2022", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2022, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Medicinal", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) Regulations 2022 \n(S.I. No. 32 of 2022)) to the Principal Regulations is amended by inserting the \nfollowing entry: \n\n“ \n\nMedicinal \nProduct \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nAdministered \nintramuscularly \n\nIndicated for \nactive \nimmunisation to \nprevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals 18 \nyears of age and \nolder \n\nNuvaxovid \ndispersion for \ninjection \n\nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\nDispersion for \ninjection, \ncolourless to \nslightly yellow, \nclear to mildly \nopalescent \n\ndispersion free \nfrom visible \nparticles in a \nmultidose vial. \n\nOne dose (0.5 \nmL) contains 5 \nmicrograms of \nthe SARS-CoV2 spike protein \n\nAny suitable \nand appropriate \nplace, having \nregard to public \nconvenience \nand the need to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAdministered as a \ncourse of 2 doses \n(0.5 mL each) at \nsuch interval as \nmay be specified \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 18th February, 2022. \n\n \n \n \n \n \n \n \n \n \n \n\fand is \nadjuvanted \n\nwith Matrix-M \n\n[57] 3 \n\nin such \nrecommendations \nor guidelines. \n\nNotwithstanding \nany directions to \nthe contrary in the \nsummary of \nproduct \ncharacteristics— \n\n(a) a dose may be \nadministered as \npart of a \nheterologous \nprimary schedule, \n\n(b) an additional \ndose may be \nadministered to \nimmunocompromi\nsed persons who \nare 18 years of \nage or older and \nhave already \nreceived a primary \nvaccine course \nagainst Covid-19, \nand \n\n(c) a booster dose \nmay be \nadministered to— \n\n(i) persons who \nare 18 years of \nage or older and \nhave already \nreceived a primary \nvaccine course \nagainst Covid-19, \nand \n\n(ii) \nimmunocompromi\nsed persons who \nare 18 years of \nage or older and \nhave already \nreceived an \nadditional dose of \na Covid-19 \nvaccine, \n\nin such volumes, \nat such intervals, \nin such manner \nand in such order \nof prioritisation \n(whether by \nreference to age, \nemployment \nsector, pregnancy \nor otherwise), as \nmay be specified \nin such \n\n \n \n \n \n \n \n \n \n\f4 [57] \n\nrecommendations \nor guidelines, and \nsubject to \ninformed consent \nbeing obtained. \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 3 medicinal product (prescription control supply) (amendment) regulation 2022 (s.i no 32 2022)) principal regulation amended inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration place administration column 1 column 2 column 3 column 4 column 5 column 6 administered intramuscularly indicated active immunisation prevent covid-19 caused sars-cov-2 virus individual 18 year age older nuvaxovid dispersion injection covid-19 vaccine (recombinant adjuvanted) dispersion injection colourless slightly yellow clear mildly opalescent dispersion free visible particle multidose vial one dose (0.5 ml) contains 5 microgram sars-cov2 spike protein suitable appropriate place regard public convenience need protect health safety public safely administer product accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health administered course 2 dos (0.5 ml each) interval may specified notice making statutory instrument published iris oifigiuil 18th february 2022 adjuvanted matrix-m 57 3 recommendation guideline notwithstanding direction contrary summary product characteristics-- (a) dose may administered part heterologous primary schedule (b) additional dose may administered immunocompromi sed person 18 year age older already received primary vaccine course covid-19 (c) booster dose may administered to-- (i) person 18 year age older already received primary vaccine course covid-19 (ii) immunocompromi sed person 18 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified 4 57 recommendation guideline subject informed consent obtained", "start_char": 1066, "end_char": 3773, "source_path": "downloads\\2022\\2022_0056.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6fbfaba414b8fa4eff5860fed25d8d4c08179d960350a1ead1df62c53e4611b1", "cross_refs": []}
{"doc_id": "si-2022-0057-reg-4", "parent_doc_id": "si-2022-0057", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 57 of 2022", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2022, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Medicinal", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 15) \nRegulations 2021 (S.I. No. 718 of 2021)) to the Principal Regulations is amended \nby inserting the following entry: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nIndication for \nwhich the \nmedicinal \nproduct may be \nadministered \n\nDosage and conditions \nof administration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nAdministered \nIntramuscularly \n\nIndicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2 \nvirus, in \nindividuals 18 \nyears of age and \nolder \n\nNuvaxovid \ndispersion for \ninjection \n\nCOVID-19 \nVaccine \n(recombinant, \nadjuvanted) \n\nDispersion for \ninjection, \ncolourless to \nslightly \nyellow, clear \nto mildly \nopalescent \n\ndispersion \nfree from \nvisible \nparticles in a \nmultidose \nvial. \n\nOne dose (0.5 \nmL) contains \n5 micrograms \nof the SARSCoV-2 spike \nprotein and is \nadjuvanted \n\nwith \nMatrix-M \n\nIn accordance with \nrelevant \nrecommendations or \nguidelines issued by the \nNational Immunisation \nAdvisory Committee \nand accepted by the \nMinister for Health. \n\nAdministered as a \ncourse of 2 doses (0.5 \nmL each) at such \ninterval as may be \nspecified in such \nrecommendations or \nguidelines. \n\nNotwithstanding any \ndirections to the \ncontrary in the summary \nof product \ncharacteristics— \n\n(a) a dose may be \nadministered as part of \na heterologous primary \nschedule, \n\n(b) an additional dose \nmay be administered to \nimmunocompromised \npersons who are 18 \nyears of age or older \nand have already \nreceived a primary \n\n \n \n \n \n \n \n \n\f[57] 5 \n\nMedicinal \nproduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nIndication for \nwhich the \nmedicinal \nproduct may be \nadministered \n\nDosage and conditions \nof administration \n\nvaccine course against \nCovid-19, and \n\n(c) a booster dose may \nbe administered to— \n\n(i) persons who are \n18 years of age or \nolder and have \nalready received a \nprimary vaccine \ncourse against \nCovid-19, and \n\n(ii) \nimmunocompromis\ned persons who are \n18 years of age or \nolder and have \nalready received an \nadditional dose of a \nCovid-19 vaccine, \n\nin such volumes, at \nsuch intervals, in such \nmanner and in such \norder of prioritisation \n(whether by reference \nto age, employment \nsector, pregnancy or \notherwise), as may be \nspecified in such \nrecommendations or \nguidelines, and subject \nto informed consent \nbeing obtained. \n\n”. \n\nGIVEN under my Official Seal, \n\n15 February, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [57]", "text_norm": "4 twelfth schedule (as amended regulation 4 medicinal product (prescription control supply) (amendment) (no 15) regulation 2021 (s.i no 718 2021)) principal regulation amended inserting following entry medicinal product route administration form presentation product administered indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 administered intramuscularly indicated active immunisation prevent covid19 caused sars-cov-2 virus individual 18 year age older nuvaxovid dispersion injection covid-19 vaccine (recombinant adjuvanted) dispersion injection colourless slightly yellow clear mildly opalescent dispersion free visible particle multidose vial one dose (0.5 ml) contains 5 microgram sarscov-2 spike protein adjuvanted matrix-m accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health administered course 2 dos (0.5 ml each) interval may specified recommendation guideline notwithstanding direction contrary summary product characteristics-- (a) dose may administered part heterologous primary schedule (b) additional dose may administered immunocompromised person 18 year age older already received primary 57 5 medicinal product route administration form presentation product administered indication medicinal product may administered dosage condition administration vaccine course covid-19 (c) booster dose may administered to-- (i) person 18 year age older already received primary vaccine course covid-19 (ii) immunocompromis ed person 18 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained  given official seal 15 february 2022 stephen donnelly minister health 6 57", "start_char": 3773, "end_char": 6458, "source_path": "downloads\\2022\\2022_0056.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6fbfaba414b8fa4eff5860fed25d8d4c08179d960350a1ead1df62c53e4611b1", "cross_refs": []}
{"doc_id": "si-2022-0057-explanatory-note", "parent_doc_id": "si-2022-0057", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 57 of 2022", "title": "Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to update the relevant schedules in relation \nto the COVID-19 vaccines to include the Nuvaxovid vaccine. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 2) Regulations 2022. \n\n \n \n \n \n \n \n \n \n\f[57] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-381) 75. 2/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation update relevant schedule relation covid-19 vaccine include nuvaxovid vaccine regulation may cited medicinal product (prescription control supply) (amendment) (no 2) regulation 2022 57 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.00 (dh-381) 75 2 22 propylon", "start_char": 6458, "end_char": 7464, "source_path": "downloads\\2022\\2022_0056.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6fbfaba414b8fa4eff5860fed25d8d4c08179d960350a1ead1df62c53e4611b1", "cross_refs": []}
